Kynexis
North Holland, Netherlands · Biotechnology, Health Care, Therapeutics
Kynexis is a clinical-stage biotechnology company focused on improving cognition for people living with brain diseases. The company is advancing KYN-5356, a potential first-in-class investigational medicine aimed at treating cognitive impairment associated with schizophrenia. Kynexis aims to address cognitive dysfunction across multiple neurological and neurodegenerative disorders. The company is
Key facts
- Headquarters
- North Holland, Netherlands
- Employees
- 21
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Private
- Website
- kynexis.io
- Company page
Recent activity at Kynexis
Kynexis funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Series A | $40.0M |
Companies similar to Kynexis
- CytoDyn · Biotechnology, Health Care, Therapeutics
- PDS Biotech · Biotechnology, Health Care, Therapeutics
- Inoviq Ltd · Biotechnology, Health Care, Therapeutics
- NRx Pharmaceuticals · Biotechnology, Health Care, Therapeutics
- TRIMTECH Therapeutics · Biotechnology, Health Care, Therapeutics
About Kynexis: questions and answers
What does Kynexis do?
Kynexis is a clinical-stage biotechnology company focused on improving cognition for people living with brain diseases. The company is advancing KYN-5356, a potential first-in-class investigational medicine aimed at treating cognitive impairment associated with schizophrenia. Kynexis aims to address cognitive dysfunction across multiple neurological and neurodegenerative disorders. The company is
Where is Kynexis headquartered?
Kynexis is headquartered in North Holland, Netherlands.
How many employees does Kynexis have?
Kynexis has about 21 employees.
Has Kynexis raised funding?
Yes. Fundz has recorded 1 funding event for Kynexis. The most recent, Series A of $40.0M, was in Aug 2026.
What is the latest news on Kynexis?
On Aug 19, 2026, Kynexis extends its Series A funding by €40 million, bringing the total to €97 million. The funding, led by Novartis Venture Fund, will support Phase 2 studies for its cognitive medicine.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy